Skip to main content
Premium Trial:

Request an Annual Quote

Iverson, Vanderbilt Partner on MDx for Breast Cancer Risk in Menopausal Women

NEW YORK (GenomeWeb News) – Iverson Genetic Diagnostics announced a collaboration with Vanderbilt University aimed at molecular diagnostics to assess breast cancer risk in menopausal women.

The test would help physicians assess the risk of breast cancer in women who are considering hormone replacement therapy during menopause.

The terms of the deal gives Iverson global, exclusive commercialization rights for the molecular diagnostic, and Dean Sproles, CEO of Iverson, said in a statement that the firm anticipates including the new test in the Women's Health segment of Iverson's Physician's Logic portfolio later this year.

Other terms of the deal were not disclosed. Sproles added that his firm is considering additional partnerships with Vanderbilt in women's health and autoimmunity.

Iverson said that studies suggest that estrogen metabolites may be a determinant of breast cancer risk. Specific enzymes regulate the pathways associated with estrogen metabolism, and corresponding genes code for the synthesis of these enzymes. Mutations of these genes are common and have been associated with an increased risk for cancer, it said.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.